These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26598624)

  • 1. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
    Nikesitch N; Tao C; Lai K; Killingsworth M; Bae S; Wang M; Harrison S; Roberts TL; Ling SC
    Blood Cancer J; 2016 Jun; 6(6):e432. PubMed ID: 27284736
    [No Abstract]   [Full Text] [Related]  

  • 3. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
    Bai Y; Su X
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
    Barrio S; Stühmer T; Da-Viá M; Barrio-Garcia C; Lehners N; Besse A; Cuenca I; Garitano-Trojaola A; Fink S; Leich E; Chatterjee M; Driessen C; Martinez-Lopez J; Rosenwald A; Beckmann R; Bargou RC; Braggio E; Stewart AK; Raab MS; Einsele H; Kortüm KM
    Leukemia; 2019 Feb; 33(2):447-456. PubMed ID: 30026573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
    Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
    Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
    EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
    Allmeroth K; Horn M; Kroef V; Miethe S; Müller RU; Denzel MS
    Leukemia; 2021 Mar; 35(3):887-892. PubMed ID: 32690882
    [No Abstract]   [Full Text] [Related]  

  • 11. Exosome-Transmitted
    Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
    Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in proteasome inhibitor-based cancer therapies.
    Dou QP
    Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
    Manasanch EE; Korde N; Zingone A; Tageja N; Fernandez de Larrea C; Bhutani M; Wu P; Roschewski M; Landgren O
    Leuk Lymphoma; 2014 Aug; 55(8):1707-14. PubMed ID: 24261677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitors: introduction.
    Heuck CJ; Shaughnessy JD
    Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
    Bianchi G; Ghobrial IM
    Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
    Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
    Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
    Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
    Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.